Lurbinectedin as monotherapy was found to elicit responses in patients with relapsed small cell lung cancer (SCLC), meeting the primary endpoint of a phase II trial by both investigator review and an independent review committee.1
- PharmaMar announces positive results in its lurbinectedin monotherapy trial for small cell lung cancer. PharmaMar. Published March 25, 2019. https://bit.ly/2HSnMvC. Accessed March 25, 2019.
- Trigo JM, Leary A, Besse B, et al. Efficacy and safety of lurbinectedin (PM1183, ZEPSYRE) in small cell lung cancer (SCLC): results from a phase 2 study. J Clin Oncol. 2018;36 (suppl; abstr 8570). doi: 10.1200/JCO.2018.36.15_suppl.8570.
... to read the full story